The results of Wang et al. [11] showed that GLP-1 receptor agonist treatment is associated with decreased risks of several cancers (e.g., prostate, lung, and colon cancer), though these agonists increase the risk of thyroid cancer. The gene discussed is GLP1R; the disease is thyroid gland carcinoma.